|
1666
|
Malpighi publishes the
first recorded description of Hodgkin's disease in his paper De
viscerum structuru exercitatio anatomica
|
|
1798
|
Thomas Hodgkin born in England.
|
|
1823
|
Thomas Hodgkin
publishes his doctoral thesis Dissertatio Physiologica Inauguralis De
ABSORBENDI FUNCTIONE (Latin) in Edinburgh. |
 |
|
1825 |
Hodgkin joins the staff of
Guy's Hospital, London. |
|
1832 |
Hodgkin
publishes his paper on lymphatic disease "On Some Morbid Appearances
of the Absorbent Glands and Spleen" Published in Medico- Chirurgical
Transactions, the journal of the Medical and Chirurgical Society in London. |
|
1838 |
Richard Bright publishes his paper on lymphatic
disease "Observations on abdominal tumors and Intumescence,
Illustrated by Cases of Disease of the Spleen". |
|
1856 |
Samual Wilks publishes his paper
"Cases of Lardaceous Disease and Some Allied Affections with Remarks".
Wilks quotes Bright but he thinks his observations
original. |
|
1865 |
Wilks describes
disease further and attributes Hodgkin with discovering the disease. |
|
1872 |
Langhans publishes the
first histopathologic features of Hodgkin's Disease (German) |
|
1878 |
Greenfield publishes
the pathology of lymphomas with histopathologic features of Hodgkin's
(English) |
|
1887 |
Wilhelm
Ebstein and PK Pel both publish papers noting a cyclic fever over a period
of 1 to 2 weeks in a fair number of Hodgkin's cases. Now called Pel-Ebstein
Fever although there is controversy about this being a real indication of
Hodgkin's (see 1959). |
|
1894 |
Osler's textbook of Medicine is the first
publication to mention chemotherapy for lymphoma (Fowler's solution - an
arsenic containing medicinal). |
|
1898 |
Carl Sternberg first
detailed description of giant cells now called Reed-Sternberg cells
(Germany) |
|
1902 |
Dorothy Reed
independently describes Reed-Sternberg cells (Johns Hopkins Hosp Rep, US) |
|
1932 |
Chevalier and Bernard reaffirm radiotherapy for Hodgkin's mostly palliative |
|
1939 |
Epstein reports better survival prognosis
for women (Epstein E, Sex as factor in the prognosis of Hodgkins disease.
Am. J. Cancer 35:230-233.) |
|
World War 2 |
Explosion in Bari,
Italy exposes servicemen to toxic effects of mustard gases. Follow-up of exposed shows marrow and lymphatic system suppression. |
|
1943 |
Nitrogen Mustard (a mustard gas
derivative) submitted to Goodman and Gilman at Yale for treatment of
Hodgkin's disease and lymphosarcoma (could be first phase I/II trial on
record). |
|
Mid-40's |
Gilbert and Craft advocate
irradiation of nodes and surrounding areas - 5 year survival reported to
be 25-35% |
|
1947 |
Alpert and
Petersen publish results of Nitrogen Mustard showing striking dissolution
of tumor masses in patients with Hodgkin's Disease and lymphosarcoma |
|
1949 |
Dameshek et al. publish paper on the use
of Nitrogen Mustard for treatment of 50 consecutive cases of Hodgkin's
|
|
1950 |
Peters reports on
unrandomized results of patients treated with high doses of radiotherapy to
both involved and adjacent sites having improved survival over those
receiving lower doses to involved sites and/or no irradiation to adjacent
sites. |
|
1959 |
Richard
Asher questions whether Pel-Ebstein Fever in 5-10% of Hodgkin's patients is
truly an indicator of Hodgkin's or just exists because it has a name. |
|
1962 |
Kaplan reports on
radiotherapy in localized Hodgkin's. Studies initiated at Stanford
1962-67 |
|
1963 |
Scott publishes paper on using chlorambucil
as maintenance chemotherapy following Nitrogen Mustard treatment for
Hodgkin's
|
|
1963 |
Development of MOMP - first combination
chemotherapy for Hodgkin's (consists of cyclophosphamide, vincristine,
methotrexate, and prednisone).
|
|
1963 |
Easson and Russell publish "The Cure
of Hodgkin's Disease" which reverses long standing belief that
Hodgkin's was incurable |
|
1964 |
Johnson et
al. publish paper on vinca alkaloid drugs (vincristine & vinblastine) |
|
1964 |
Systematic trials on the use of vinca alkaloids for
remission induction after Nitrogen Mustard vs. use of chlorambucil |
|
1964 |
MOPP combination chemotherapy derived by replacing
methotrexate with procarbazine
in MOMP |
|
1964 |
EORTC launches the H1
trial on Hodgkin's Disease |
|
Feb. 1965 |
The Paris
international workshop on radiotherapy effectiveness, histologic
classification, and staging systems. 4 stages were defined with
differentiation between B symptoms |
|
Sept. 1965 |
Conference "On Obstacles to
the Control of Hodgkin's Disease" held in Rye, NY, sponsored by ACS and
NCI. 45 leaders in the field attend. The Rye staging system developed based
on work done in Paris |
|
1965 |
MacMahon distinguishes between 3
age groups (0-14, 15-34, 50+) for Hodgkin's, each with distinctive features |
|
1966 |
Lukes and Butler describe the
Reed-Sternberg variant cells called L&H cells in nodular
lymphocyte-predominant Hodgkin's (Cancer Res) |
|
1967 |
Results of MOPP on first 43 patients: 81% complete
remission rate (a four-fold increase over single agent drugs) |
|
1967-1973 |
NCI randomized trials on
extended vs. involved field radiotherapy. Extended provides improved
progression free survival but eventual survival differences minimal due to
salvage therapies available. |
|
1968 |
Adriamycin
becomes available as a new anticancer drug |
|
1969 |
Stanford clinical trials on the
use of exploratory laparotomy / splenectomy in staging |
|
1970 |
Publication of survival curves for MOPP treated patients shows
advanced Hodgkin's is curable by combination chemotherapy |
|
April 1971 |
Ann Arbor meeting sponsored by ACS and NCI. Staging broken down into
Clinical Stage (CS) based on x-ray, lymphangiogram, & physical exam
and Pathologic Stage (PS) based on staging laparotomy, splenectomy, liver
biopsy, open marrow biopsy and additional node biopsy. Generalized
pruitis (itching) dropped from list of B symptoms. |
|
1972 |
Arseneau et al. report on secondary cancers
following therapy for Hodgkin's disease |
|
1972 |
Frei et al. report remission success of 56% in untreated patients
with Hodgkin's treated using dacarbazine |
|
1973 |
Sherins et al. report on male reproductive function
in those in remission following treatment for Hodgkin's. |
|
1973 |
Bonadonna et al. from Italy report on trials of adriamycin,
bleomycin, vinblastine and imidazole carboxamide verses MOPP
combination chemotherapy |
|
1974-1982 |
Randomized
studies on effectiveness of ABVD or MOPP before and after irradiation in
stage IIB and stage III A&B at Milan Cancer Institute |
|
|
Randomized studies comparing 12 cycles of MOPP
verses monthly alternating with ABVD in stage IV disease |
|
1974 |
Rosdahl,
Larsen, and Clemmesen study Hodgkin's disease in patients with previous
infectious mononucleosis. Note: mononucleosis is caused by the
Epstein-Barr virus (EBV) investigated by MA Epstein in the 1960s. Brit.
Med. J. 1:253-355 |
|
1975 |
Therapeutic
antibodies are developed by Cesar Milstein and Georges Kohler. This
work will lay the foundation for modern immunotherapy
and monoclonal antibody therapy.
They will win the Nobel Prize in 1984 for their work. |
|
1976-1982 |
EORTC H5 trials |
|
1978 |
NCI study on the use of MOPP alone verses subtotal
nodal irradiation shows MOPP superior in both relapse-free and overall
survival. |
|
1979 |
BNLI compares MOPP with
LOPP (leukeran/chlorambucil replaces mechlorethamine |
|
1982 |
First paper on long term (LT) follow-up of ovarian
function in women treated with MOPP by Shilsky et al. |
|
1983 |
Microsoft cofounder
Paul
Allen leaves the company after a diagnosis of Hodgkin's Disease.
He achieves remission and goes to found a number of successful companies. |
|
1986 |
MOPP/ABV hybrid chemotherapy developed and published
by Canadian researchers. |
|
1987 |
Weiss,
et al. using Southern Blot, detect Epstein-Barr virus (EBV) viral DNA in
tissues of Hodgkin's disease Am J Pathol 1987;129:86.
Herbst et al. and Weiss et al. confirm via PCR in 1990 and 1991
respectively. |
|
1987 |
EBVP (epirubicin,
bleomycin, vinblastine, prednisone) introduced by Zittoun
and tested in EORTC H7 trial. |
|
1991 |
The Lymphoma Research Foundation of America
(LRFA), was founded by Ellen Glesby Cohen in Los Angeles, California USA |
|
1992 |
Bulky disease (node or nodal mass > 10 centimeters in size)
regarded as important in Hodgkin's staging. |
|
1992 |
The
German Hodgkin's Study Group designed the BEACOPP regimen that used similar
drugs as in the COPP/ABVD
regimen, excluding velban
and dacarbazine and adding etoposide,
trying to increase efficacy. |
|
1994 |
Amanda Gee, a Hodgkin's patient
in the UK, starts the first web site
devoted to Hodgkin's Disease |
|
Nov. 1994 |
Cure for Lymphoma Foundation
founded in New York, New York USA |
|
1994 |
First
hints that Hodgkin's cancerous cells are derived from B lymphocytes.
Confirmed in 1999 (below). Source |
|
1995 |
Stanford reports on use of
Stanford V chemotherapy and adjuvant radiotherapy for bulky / advanced
Hodgkin's Disease |
|
Dec 1994 |
Mike Barela, a recent Hodgkin's
survivor in the US, launches the first combined Hodgkin's / Non-Hodgkin's
Lymphoma web resource list site Lymphoma Resource Pages, later to become the
Lymphoma Information Network |
|
1997 |
Rituxan
approved for b-cell Non-Hodgkin's lymphoma.
With the discovery in 1999 that Reed-Sternberg cells are derived from B
lymphocytes, research can proceed on the effectiveness of monoclonal
antibodies in Hodgkin's. |
|
1999 |
Kapp et al. report on role of
Intereukin-13 on the growth and stimulation of Hodgkin and Reed-Sternberg
cells. |
|
1999
|
Cossman
et al. report definitive proof that Reed-Sternberg cells in Hodgkin's
Lymphoma are derived
from germinal-center B lymphocytes |
|
2001
|
The WHO
Classification for Lymphomas published - the term Hodgkin's Lymphoma is
the preferred designation over Hodgkin's Disease |
|
2002
|
LRFA and CFL merge to form the
Lymphoma Research Foundation in the US |
|
2002
|
Horning
et. al. present results from phase II trial on rituxan
for lymphocyte predominant Hodgkin's |
|
July 2003
|
Younes
et al. publish a pilot study of rituxan
in patients with recurrent, classic Hodgkin's disease |
|
Nov. 2005
|
Klimm et
al. in Germany further study Hodgkin's prognosis of Men vs. Women (see E.
Epstein 1939 above) Journal of Clinical Oncology,
Vol 23, No 31 (November 1), 2005: pp. 8003-8011 |
|
Dec. 2005
|
Mathas
et al. determine the mechanism that causes normal B lymphocytes to
mutate into the cancerous cells in Hodgkin's lymphoma |
|
Dec 2005
|
Robertson,
Knight, and Sharma determine the link between Epstein-Barr Virus (EBV)
and several cancers including Hodgkin's lymphoma via molecular elimination
of the retinoblastoma protein (Rb) |
|
Oct. 2008
|
Lamprecht
and Mathas discover Interleukin-21 (IL-21) is produced by Hodgkin's
cancer cells (only thought until now to be in T Cells). This explains
a great deal of the behavior of Hodgkin's including alot of other immune
cells clustered around HD cells in cultures. Targeting IL-21 may be a
potential treatment, possibly a test for the disease. Journal: Blood, Vol
112, No. 8, 2008, 3339-3347 |
|
|
